Gene Therapy Zynteglo denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for gene therapy zynteglo are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Zynteglo as Not FDA-Approved — and Why You Can Appeal

A "not FDA-approved" denial for Zynteglo (betibeglogene spartacus) is almost certainly an administrative error or an outdated policy classification. Zynteglo received full FDA approval for the treatment of transfusion-dependent beta-thalassemia. If BCBS has issued this denial, it likely reflects a lag in the plan's internal drug database, a coding mismatch, or the denial was issued under a template that did not reflect the current regulatory status of the drug.

## Why This Denial Is Appealable

Denials grounded in incorrect facts — specifically a false assertion that an FDA-approved drug lacks approval — are among the most straightforwardly reversible on appeal. The appeal simply needs to place the FDA approval record in front of the reviewer. Under ERISA §503, plans must provide a "full and fair review," which cannot be satisfied when the factual basis of the denial is wrong.

## Federal Appeal Framework

• Internal appeal (Level 1): File under ACA §2719 / ERISA §503 within the deadline on your denial letter (typically 180 days). Include the FDA approval evidence directly. Many not-FDA-approved denials are reversed at Level 1 once the record is corrected.
• External review: If the internal appeal fails, request IRO review under ACA §2719. The window is typically 4 months from the final adverse determination — verify the exact date on your notice.
• Expedited option: Request expedited review (72-hour decision) if delay would seriously jeopardize health.

## Documentation to Gather

1. FDA approval documentation: Print the official FDA drug approval page for Zynteglo from FDA.gov. Include the indication statement and the approval date. 2. FDA prescribing label: The current full prescribing information, which lists the approved indication, available directly from FDA.gov or the manufacturer. 3. Indication match: Your prescriber's confirmation that the patient's diagnosis (transfusion-dependent beta-thalassemia) matches the FDA-approved indication. 4. Denial letter: A copy of the original denial with the specific not-FDA-approved language, so the appeal letter can directly rebut each stated basis. 5. Medical-necessity letter: A brief prescriber letter confirming the diagnosis, the FDA-approved indication match, and the clinical rationale for the therapy.

## Criteria-Mapping Structure

Because the denial rests on a factual error, the criteria map is narrow but must be airtight:

| Denial Basis | Rebuttal Evidence | |---|---| | Drug lacks FDA approval | [FDA.gov approval page — print with URL and approval date] | | Indication not approved | [FDA prescribing label indication section; prescriber diagnosis confirmation] | | Plan policy requires FDA approval for coverage | [Plan's own policy language + FDA approval record = criteria met] |

Begin your appeal letter with a clear, factual correction: state the FDA approval date, cite FDA.gov, and attach the documentation. Keep the tone factual and non-adversarial. If BCBS's Level 1 reviewer has access to the correct regulatory information, this denial type frequently resolves at the first appeal level.